Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition
Corresponding Author
M. Napolitano
Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy
Search for more papers by this authorM. Megna
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
Search for more papers by this authorG. Fabbrocini
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
Search for more papers by this authorS.P. Nisticò
Department of Health Sciences, University Magna Graecia, Catanzaro, Italy
Search for more papers by this authorN. Balato
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
Search for more papers by this authorS. Dastoli
Department of Health Sciences, University Magna Graecia, Catanzaro, Italy
Search for more papers by this authorC. Patruno
Department of Health Sciences, University Magna Graecia, Catanzaro, Italy
Search for more papers by this authorCorresponding Author
M. Napolitano
Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy
Search for more papers by this authorM. Megna
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
Search for more papers by this authorG. Fabbrocini
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
Search for more papers by this authorS.P. Nisticò
Department of Health Sciences, University Magna Graecia, Catanzaro, Italy
Search for more papers by this authorN. Balato
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
Search for more papers by this authorS. Dastoli
Department of Health Sciences, University Magna Graecia, Catanzaro, Italy
Search for more papers by this authorC. Patruno
Department of Health Sciences, University Magna Graecia, Catanzaro, Italy
Search for more papers by this author
References
- 1Megna M, Balato A, Napolitano M et al. Psoriatic disease treatment nowadays: unmet needs among the “jungle of biologic drugs and small molecules”. Clin Rheumatol 2018; 37: 1739–41.
- 2Darrigade AS, Milpied B, Truchetet ME et al. Pattern and severity of psoriasiform eruptions in patients with inflammatory bowel diseases, arthritis or skin inflammatory disorders treated with TNF-alpha inhibitors. Acta DermVenereol 2017; 97: 731–4.
- 3Nakamura M, Lee K, Singh R et al. Eczema as an adverse effect of anti-TNFα therapy in psoriasis and other Th1-mediated diseases: a review. J Dermatolog Treat 2017; 28: 237–41.
- 4Pernet C, Guillot B, Bessis D. Eczematous drug eruption after ustekinumab treatment. Arch Dermatol 2012; 148: 959–60.
- 5Burlando M, Cozzani E, Russo R, Parodi A. Atopic-like dermatitis after secukinumab injection: a case report. Dermatol Ther 2018; 20: e12751.
- 6Dumont-Berset M, Laffitte E, Gerber C et al. Eczematous drug eruption after infliximab. Br J Dermatol 2004; 151: 1272–3.
- 7Esmailzadeh A, Yousefi P, Farhi D et al. Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: a cohort study of 92 patients. Dermatology 2009; 219: 263–7.
- 8Stoffel E, Maier H, Riedl E et al. Analysis of anti-tumour necrosis factor-induced skin lesions reveals strong T helper 1 activation with some distinct immunological characteristics. Br J Dermatol 2018; 178: 1151–62.
- 9Mangan PR, Su LJ, Jenny V et al. Dual inhibition of interleukin-23 and interleukin-17 offers superior efficacy in mouse models of autoimmunity. J Pharmacol Exp Ther 2015; 354: 152–65.
